Cargando…
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Targeted T cells are emerging as effective non-toxic therapies for cancer. Multiple elements, however, contribute to the overall pathogenesis of cancer through both distinct and redundant mechanisms. Hence, targeting multiple cancer-specific markers simultaneously could result in better therapeutic...
Autores principales: | Grada, Zakaria, Hegde, Meenakshi, Byrd, Tiara, Shaffer, Donald R, Ghazi, Alexia, Brawley, Vita S, Corder, Amanda, Schönfeld, Kurt, Koch, Joachim, Dotti, Gianpietro, Heslop, Helen E, Gottschalk, Stephen, Wels, Winfried S, Baker, Matthew L, Ahmed, Nabil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731887/ https://www.ncbi.nlm.nih.gov/pubmed/23839099 http://dx.doi.org/10.1038/mtna.2013.32 |
Ejemplares similares
-
A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma
por: Hegde, Meenakshi, et al.
Publicado: (2015) -
Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.
por: Ahmed, Nabil, et al.
Publicado: (2015) -
Dual targeting of the tumor and its associated vasculature using a single bispecific chimeric antigen receptor molecule
por: Byrd, Tiara, et al.
Publicado: (2014) -
A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy
por: Muhammad, Niaz, et al.
Publicado: (2022) -
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
por: Hegde, Meenakshi, et al.
Publicado: (2020)